ClinicalTrials.gg
Not yet recruitingNCT07948876Updated Nov 19, 2026

Non-anaemic Iron Deficiency and Iron Supplementation in Girls 15-18 Yrs

An interventional study of SiderAL-Forte iron supplement in Non-anaemic Iron Deficiency, Psychiatric Disorders and Adolescent, sponsored by Lund University Hospital. Not yet recruiting at 1 site in Sweden. Open to female participants aged 15 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Lund University Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
15 Years to 18 Years
Sex
Female
01

Study summary

The goal of this observational study is to investigate the prevalence of iron deficiency and the association to psychiatric symptoms in girls 15-18 years attending adolescent mental health services and for those who have an iron deficit offer three months of iron supplementation to evaluate the effect on iron status and on psychiatric symptoms.

THE MAIN QUESTIONS THE STUDY AIMS TO ANSWER IS:

  1. How prevalent is iron deficiency in girls age 15-18 years in adolescent mental health?
  2. Is iron deficiency associated to psychiatric symptoms?
  3. Does iron supplementation with SiderAL- forte, a mild nutritional supplement, improve iron stores and psychiatric symptoms? Is the supplementation well tolerated?
  4. Qualitatively: How do participants describe their understanding of well-being and regarding being informed of low iron stores?How do participants experience iron supplementation and factors that hinder or facilitate treatment?

WHAT IS THE ACTIVITY FOR THE PARTICIPANT?

  • The ongoing treatment at the service is not affected.
  • Blood sampling at the local clinic or with the general practioner and online self report forms are collected at baseline.
  • Participants with iron deficiency will be offered iron supplementation with SiderAL- forte, a mild nutritional supplement for three months.
  • Blood sampling and online self report forms will be collected at 3 and 6 months after start of iron supplementation.
Read the detailed description

Background Iron deficiency (ID) is common and affect people of all ages, but especially women of reproductive age. About one third of women in North America and 30-40% of adolescent girls in Sweden have ID. Anaemia, i.e. low haemoglobin, is a late consequence of depleted iron stores, and most iron deficiencies still have a haemoglobin within the normal range. Iron is important for transportation and storage of oxygen, but also for neurogenesis, myelination, and neurotransmitter synthesis in the central nervous system. ID typically develops gradually over time, and can remain undiagnosed and untreated. Low serum ferritin is always caused by iron deficiency and is used as an indicator of low iron stores. The WHO cut-off for ID is ferritin levels \<15 µg/L. However, this cut-off is argued to be too low, since it is highly suggestive for ID with anaemia but lacks sensitivity for ID without anaemia (IDWA). Ferritin levels of \<30 µg/L is suggested as a cut-off for detecting ID among adults, while studies on children and adolescents are scarce. Oral iron supplementation is the first-line treatment for IDWA.

IDWA is associated with psychiatric symptoms such as depression and anxiety, fatigue, inattention, memory difficulties, and disturbed sleep. Low ferritin is associated with ADHD in children. In adolescence, which is a critical period for brain development, IDWA is associated with lower basal ganglia iron content, which in turn is linked to is more depressive symptoms and lower neuropsychological performance. Importantly, the developing adolescent requires more iron because of increased blood volume, rising haemoglobin levels, and increased enzyme production.

Iron supplementation can elevate ferritin levels and improve cognitive performance in women, and furthermore improve aerobic capacity in athletes with IDWA. A recent meta-analysis on iron supplementation for IDWA in children, adolescents, and menstruating women, showed improvements in fatigue, anxiety, physical well-being and short-term memory.

As noted above, studies on IDWA in adolescents are few, particular within Child and Adolescent Mental Health Services (CAMHS). Existing evidence suggests that ferritin levels are lower among children and adolescents attending CAMHS than in the general adolescent population, and one study shows a prevalence approaching 45% for IDWA among inpatient girls. A pilot study on adolescent girls with depression or anxiety disorders found that lower ferritin levels were associated with a higher degree of internalizing symptoms. One small open study (n=19) on iron supplementation for children and adolescents with ferritin \<30 µg/L in a CAMHS setting found improved ferritin levels and improvements in depression and sleep. Another small study (n=10) from the same research group found improvements in anxiety, inattention, depression, fatigue, and sleep after iron supplementation for children and adolescents with ferritin \<50 µg/L.

In summary, IDWA may be common among adolescent girls attending CAMHS and could contribute to psychiatric symptoms and functional impairment while remaining unrecognised and untreated. However, its prevalence in CAMHS, the extent to which iron status is associated with different psychiatric symptom domains and functioning, and outcomes following iron supplementation in this population remain poorly understood. The present study addresses these gaps by combining large-scale screening and cross-sectional symptom assessment with prospective follow-up of girls with IDWA receiving iron supplementation.

Objectives The primary aim of the cross-sectional study is to estimate the prevalence of iron deficiency without anaemia (IDWA) among girls aged 15-18 years attending CAMHS. Secondary aims are to examine associations between plasma ferritin levels, psychiatric symptoms, and functional impairment, and whether these associations vary by age.

The primary aim of the open trial is to examine changes in psychiatric symptoms and functional impairment following iron supplementation among girls with IDWA, defined as plasma ferritin \<30 µg/L. Secondary aims are to assess side effects and adherence, changes in plasma ferritin and haemoglobin, and whether increases in ferritin are associated with improvements in psychiatric symptoms and functioning. An exploratory aim is to identify ferritin levels below which supplementation is associated with greater clinical improvement.

Study design The first phase is a cross-sectional study screening for plasma ferritin levels in girls aged 15-18 years who have had at least one visit at a CAMHS clinic in Region Halland during the preceding year. Based on administrative data, we estimate that around 1500 patients will be eligible and that around 750 will consent. Participants will be assessed with blood samples and web-based self-reporting scales on psychiatric symptoms.

The second phase is an open trial of iron supplementation for three months in participants with a plasma ferritin below 30 µg/L at baseline, with follow-ups at three, six and twelve months after baseline.

Participants Inclusion criteria for the cross-sectional study are girls aged 15-18 who have had at least one visit at a CAMHS clinic in Region Halland during the preceding year, with no exclusion criteria. Patients will be identified through a scanning of the outpatient administrative files. They will be contacted by text message with brief information about the study and an invitation to participate. There will be a link to a homepage with participant information. Patients who have not responded will receive an invitation by letter with participant information. After consent, the web-based questionnaire regarding symptoms will be sent electronically. When questionnaires are filled in, the blood tests will be issued. The participant will be informed not to have the blood drawn if ill by an acute infection but to wait until the infection has abated. Results of laboratories will be sent by text messages including the following suggestions: 1) referral to general practitioner in case of a) anaemia (haemoglobin \<116 mg/mL), b) ferritin >200 µg/L, or c) CRP >30 mg/mL; 2) invited to a second blood test after three or more weeks if C-Reactive Protein (CRP) 2-30 mg/mL; and 3) invited to participate in the open trial of iron supplementation if ferritin \<30 µg/L and CRP \<2 mg/mL.

Inclusion criteria for the open trial is participants from the open trial with plasma ferritin \<30 µg/L and CRP \<2 mg/mL. Exclusion criteria for the open trial are: a) ongoing iron supplementation, b) Hb \<116 mg/mL, and c) CRP >2 mg/mL.

Treatment Participants in the open study will be provided free of charge nutritional supplementation with iron (SiderAL Forte) to be taken once daily for three months. SiderAL Forte utilises a liposomal technology which increases bioavailability and possibly reduces side-effects. SiderAL Forte contains 30 mg of iron and 70 mg of vitamin C to enhance uptake. It appears to have similar effects as higher doses of ferrous iron. Participants will be offered support regarding side-effects through text messages or phone.

The regular treatment at the CAP clinic will continue fully separated from the open trial. Clinicians will receive a notice that iron supplementation is ongoing, and that secure handling of the iron related to risk of intentional overdosing is a responsibility of the clinician in line with the safety precautions of the other medications that are part of the treatment at the clinic.

Statistics A cross-sectional sample of 750 participants will provide good precision for estimating the prevalence of IDWA. Assuming a prevalence of 30%, the expected 95% confidence interval is approximately 27-33%. Across plausible prevalence estimates ranging from 10% to 60%, the corresponding margin of error is approximately ±2-4 percentage points. This sample also provides 80% power to detect correlations as small as r = 0.10 at an alpha level of 0.05. An open-trial sample of 250 participants provides approximately 88% power to detect a small within-group change (Cohen's d = 0.20) from baseline to 6 months. Recruitment will therefore continue until 750 participants have been included in the cross-sectional study.

For the open trial, we aim to include 250 participants with IDWA. A sample of this size provides approximately 88% power to detect a small within-group change of Cohen's d = 0.20 from baseline to 6 months at an alpha level of 0.05. Recruitment to the cross-sectional study will continue until 750 participants have been included, with an anticipated open-trial sample of approximately 250 participants.

Demographic data will be summarised using descriptive statistics. In the cross-sectional study, the prevalence of IDWA will be estimated using ferritin thresholds of \<15, and \<30 µg/L, with corresponding 95% confidence intervals. Associations between ferritin levels, psychiatric symptoms, and functional impairment will be examined using correlations and regression models adjusting for relevant covariates, including age.

In the open trial, missing data will first be addressed using multiple imputation by chained equations. The imputation model will include variables from the primary analyses as well as relevant auxiliary variables that predict missingness or the variables being imputed. The number of imputations will be selected to provide stable estimates and may be increased depending on the amount of missing information.

Changes in psychiatric symptoms and functional impairment following iron supplementation will then be analysed using linear mixed-effects models with repeated measures. Models will include time as a fixed effect and a participant-level random intercept to account for within-person correlation. Analyses will estimate mean changes over time with 95% confidence intervals. Models will be fitted separately within each imputed dataset and estimates pooled using Rubin's rules.

Secondary analyses will examine whether within-person increases in ferritin are associated with within-person improvements in psychiatric symptoms and functional impairment. Changes in ferritin and haemoglobin will also be described, together with side effects and adherence to supplementation.

Missingness will be summarised by participant and assessment point, and associations between missingness, baseline characteristics, and previously observed outcomes will be examined to assess the plausibility of the missing-at-random assumption. Sensitivity analyses based on observed data and, if warranted, analyses examining departures from the missing-at-random assumption will be conducted.

Exploratory analyses will examine whether baseline ferritin predicts symptom trajectories by testing ferritin-by-time interactions and will explore baseline ferritin thresholds associated with clinically meaningful symptom improvement. These analyses will be considered exploratory and interpreted using effect estimates and 95% confidence intervals rather than confirmatory hypothesis testing.

Qualitative interviews Individual semi-structured interviews will be conducted approximately four months after treatment initiation, corresponding to one month after the planned three-month supplementation period. This timing allows participants to reflect on receiving their blood test results and their experiences during and after supplementation. Interviews will be conducted by a researcher experienced in qualitative interviewing who is not involved in the participant's clinical care. T. The interviews will take place either in an undisturbed setting or via a video platform, depending on the participant's preference. The interviews are expected to last approximately 30-60 minutes, will be audio-recorded following informed consent, and transcribed verbatim.

The interview guide will cover participants' well-being and everyday life; experiences of receiving and understanding their blood test results; the meaning, if any, of these results for their understanding of their own well-being; experiences of taking iron supplements, including factors that facilitate or hinder supplementation; perceived changes or lack of change in well-being and everyday life; and experiences of information, communication and support from healthcare professionals. Open-ended questions and follow-up prompts will encourage participants to describe their experiences in their own words and provide concrete examples, without presupposing that the test results or supplementation had any particular significance for them.

02

Conditions studied

  • Non-anaemic Iron Deficiency
  • Psychiatric Disorders
  • Adolescent

Keywords

  • fatigue
  • anxiety
  • depression
  • adhd
  • ferritin
  • iron supplementation
  • observational
03

In context

Mental Disorders

1,745 studies on the registry are indexed under Mental Disorders; 351 are open to participants now.

This study's planned enrollment of 250 is above the median of 100 across 1,304 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Lund University Hospital is the lead sponsor of 68 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Attending the Child and Adolescent Mental Health Services at Region Halland, Sweden during December 2025-November 2026;
  • Plasma-Ferritin below 30 microgram/L

Exclusion criteria

Exclusion Criteria:

  • below 116 g/L
  • Ongoing iron supplementation/treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Dietary supplement with iron

    Dietary Supplement: SiderAL-Forte iron supplement

Interventions

  • Dietary supplementSiderAL-Forte iron supplement

    SiderAL-Forte contains 30 mg of ferrous iron and 70 mg of vitamin C

06

What researchers measure

Primary outcomes

  1. The PROMIS paediatric fatigue scale

    Change from baseline to three (primary) and six (secondary) months for The PROMIS paediatric fatigue scale is a 10 item scale evaluating symptoms of fatigue in children and adolescents, with responses on a five point Likert scale ranging from 1 (never) to 5 (almost always) with total score ranging from 10-50. Total scores are converted to T-scores. A higher score is worse. The PROMIS paediatric fatigue scale is translated into Swedish, validated in a Swedish CAP setting and has shown acceptable psychometric properties.

    Time frame: one week

Secondary outcomes

  1. The Revised Child Anxiety and Depression Scale (RCADS-30)

    Change from baseline to follow-up at 3 and 6 months in the Revised Child Anxiety and Depression Scale, a youth self-report questionnaire for ages 8-18 years with items on a four-point Likert scale from 0 (none) to 3 (always) and subscales including: separation anxiety disorder, social phobia, generalized anxiety disorder, panic disorder, obsessive compulsive disorder, and low mood (major depressive disorder). Total scores ranges from 0 to 90. A higher score is worse. RCADS-30 is an abbreviated version, where all the original scales are retained, with good psychometric properties.

    Time frame: one week

  2. The ADHD Self-Report Scale for Adolescents (ASRS)

    ASRS is an abbreviated 18-item questionnaire aligning with DSM-5 with a four point Likert scale from 0 (none) to 3 (always). Total score ranges from 0 to 54, higher is worse. It has shown good psychometric properties.

    Time frame: one week

  3. Irritability (IDAS-II)

    The Irritability subscale comprises with five items from the Inventory of Depression and Anxiety Symptoms scored from 1 (not at all) to 5 (extremely). Total score ranges from 5 to 25. A higher score is worse.

    Time frame: one week

  4. Functioning (UFID)

    The Uppsala scale of Functional Impairment in Daily life to capture how mental health problems and mental disorders affect global functioning across five core domains: family relationships, self-care and daily routines, schoolwork, peer relationships, and leisure activities. Each domain is rated on a five-point Likert scale from = (functioning well) to 4 (not functioning at all), yileding a total score ranging from 0 to 20, with higher scores indicating rgeater impairment.

    Time frame: one week

  5. KIDSCREEN

    Kidscreen-10 is a self-rating scale on health related quality of life with ten items ranging from 1 (not at all/never) to 9 (extremely/always). Total score ranges from 10 through 90 with higher scores indicating a better quality of life.

    Time frame: one week

  6. Ferritin

    Ferritin is an iron binding protein and the best non-invasive marker for iron deficiency. It detects iron defiency before the development of anemia. WHO standards has a cut off at 15 micrograms/liter for iron defiency while recent consensus suggests a cut off at 30 15 micrograms/liter. Lower is worse. Ferritin is also an acute phase reactant and increased ferritin can thus result from a concomitant inflammation. To control for this false negative result, another acute phase reactant (C-reactive protein) is also analyzed and deemed to be normal (less than 2 gram/liter) for the ferritin value to be indicative of iron stores.

    Time frame: periprocedural

  7. Haemoglobin

    Haemoglobin is an iron-containing protein in the red blood cells, to transport oxygen. Haemoglobin synthesis requires iron. A normal range for adolescent girls is set to 116 through 149 gram/liter while anaemia is determined by a value less than 116 gram/liter.

    Time frame: periprocedural

  8. Side effect form (P-SEC)

    Paediatric side effect checklist is custom made with six items from the Swedish package insert of iron tablets. It is scored o a four point Likert scale ranging from 0 (no problems) to 3 (severe problems/not acceptable). Each item is presented separately with no total scale values.

    Time frame: three months (since started taking supplement)

  9. Adherence (MARS-5)

    Medication Adherence Report Scale is a five item instrument for self-reported adherence to medication. It consists of five items rated on a five-point Likert scale from 1 (never) to 5 (always) with higher scores producing a total score ranging from 5 to 25. Higher scores indicate a greater self-reported medicatioin adherence.

    Time frame: three months (since started taking supplement)

07

Study locations

1 site
08

References and documents

Publications

  • Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004 Feb;24(2):105-12. doi: 10.1016/j.nedt.2003.10.001. PubMed 14769454 ↗
  • Parisi F, Berti C, Mando C, Martinelli A, Mazzali C, Cetin I. Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: a randomized control trial. J Matern Fetal Neonatal Med. 2017 Aug;30(15):1787-1792. doi: 10.1080/14767058.2016.1224841. Epub 2016 Sep 2. PubMed 27588568 ↗
  • Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 Feb 11;340(6):448-54. doi: 10.1056/NEJM199902113400607. No abstract available. PubMed 9971870 ↗
  • Adeli K, Higgins V, Trajcevski K, White-Al Habeeb N. The Canadian laboratory initiative on pediatric reference intervals: A CALIPER white paper. Crit Rev Clin Lab Sci. 2017 Sep;54(6):358-413. doi: 10.1080/10408363.2017.1379945. Epub 2017 Oct 11. PubMed 29017389 ↗
  • Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science. 2012 Nov 9;338(6108):768-72. doi: 10.1126/science.1224577. PubMed 23139325 ↗
  • Elin RJ, Wolff SM, Finch CA. Effect of induced fever on serum iron and ferritin concentrations in man. Blood. 1977 Jan;49(1):147-53. PubMed 830372 ↗
  • Jorgensen JM, Crespo-Bellido M, Dewey KG. Variation in hemoglobin across the life cycle and between males and females. Ann N Y Acad Sci. 2019 Aug;1450(1):105-125. doi: 10.1111/nyas.14096. Epub 2019 May 10. PubMed 31074518 ↗
  • Braga F, Pasqualetti S, Frusciante E, Borrillo F, Chibireva M, Panteghini M. Harmonization Status of Serum Ferritin Measurements and Implications for Use as Marker of Iron-Related Disorders. Clin Chem. 2022 Sep 1;68(9):1202-1210. doi: 10.1093/clinchem/hvac099. PubMed 35794075 ↗
  • Bohn MK, Higgins V, Asgari S, Leung F, Hoffman B, Macri J, Adeli K. Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents. Clin Chem Lab Med. 2019 Nov 26;57(12):1968-1979. doi: 10.1515/cclm-2019-0707. PubMed 31377737 ↗
  • Garcia-Casal MN, Pasricha SR, Martinez RX, Lopez-Perez L, Pena-Rosas JP. Serum or plasma ferritin concentration as an index of iron deficiency and overload. Cochrane Database Syst Rev. 2021 May 24;5(5):CD011817. doi: 10.1002/14651858.CD011817.pub2. PubMed 34028001 ↗
  • Birgegard G, Hallgren R, Killander A, Stromberg A, Venge P, Wide L. Serum ferritin during infection. A longitudinal study. Scand J Haematol. 1978 Oct;21(4):333-40. doi: 10.1111/j.1600-0609.1978.tb00374.x. PubMed 725531 ↗
  • Benson AE, Lo JO, Achebe MO, Aslan JS, Auerbach M, Bannow BTS, Boller MJ, Deloughery TG, Dingman J, Van Doren L, Dy GW, Ford PA, Freed JA, Georgieff MK, Haley KM, Han CI, Lewkowitz AK, Martens KL, Means RT Jr, Nemeth E, Olson SR, Powers JM, Prewitt KC, Richards T, Rockey DC, Roeland EJ, Ryan KS, Al-Samkari H, Sholzberg M, Tuuli MG, Weyand AC, Zeller MP, Totten AM, Ivlev I, Shatzel JJ; Iron Consortium at Oregon Health & Science University. Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendations. Lancet Haematol. 2025 May;12(5):e376-e388. doi: 10.1016/S2352-3026(25)00038-9. PubMed 40306833 ↗
  • Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol. 1973 Oct;26(10):770-2. doi: 10.1136/jcp.26.10.770. PubMed 4750458 ↗
  • Spetz K, Olbers T, Ostbring M, Moon Z, Horne R, Andersson E. Using the 5-Item Medication Adherence Report Scale (MARS-5) to Screen for Non-adherence to Vitamin and Mineral Supplementation After Bariatric Surgery. Obes Surg. 2024 Feb;34(2):576-582. doi: 10.1007/s11695-023-07027-x. Epub 2024 Jan 4. PubMed 38177555 ↗
  • Astenvald R, Isaksson M, Meyer J, Loof M, Frick MA, Isaksson J. Emotion regulation training for adolescents with ADHD: a multiple-baseline single-case experimental study. Cogn Behav Ther. 2026 Sep;55(5):728-744. doi: 10.1080/16506073.2025.2537812. Epub 2025 Aug 4. PubMed 40757988 ↗
  • Ravens-Sieberer U, Erhart M, Rajmil L, Herdman M, Auquier P, Bruil J, Power M, Duer W, Abel T, Czemy L, Mazur J, Czimbalmos A, Tountas Y, Hagquist C, Kilroe J; European KIDSCREEN Group. Reliability, construct and criterion validity of the KIDSCREEN-10 score: a short measure for children and adolescents' well-being and health-related quality of life. Qual Life Res. 2010 Dec;19(10):1487-500. doi: 10.1007/s11136-010-9706-5. Epub 2010 Jul 30. PubMed 20668950 ↗
  • Cervin M, Marti Valls C, Moller S, Frick A, Bjorkstrand J, Watson D. A Psychometric Evaluation of the Expanded Version of the Inventory of Depression and Anxiety Symptoms (IDAS-II) in Children and Adolescents. Assessment. 2024 Apr;31(3):588-601. doi: 10.1177/10731911231170841. Epub 2023 May 12. PubMed 37177831 ↗
  • Lundin A, Kosidou K, Dalman C. Testing the Discriminant and Convergent Validity of the World Health Organization Six-Item Adult ADHD Self-Report Scale Screener Using the Stockholm Public Health Cohort. J Atten Disord. 2019 Aug;23(10):1170-1177. doi: 10.1177/1087054717735381. Epub 2017 Oct 26. PubMed 29073818 ↗
  • Sonnby K, Skordas K, Olofsdotter S, Vadlin S, Nilsson KW, Ramklint M. Validation of the World Health Organization Adult ADHD Self-Report Scale for adolescents. Nord J Psychiatry. 2015 Apr;69(3):216-23. doi: 10.3109/08039488.2014.968203. Epub 2014 Oct 28. PubMed 25348323 ↗
  • Adler LA, Shaw DM, Spencer TJ, Newcorn JH, Hammerness P, Sitt DJ, Minerly C, Davidow JV, Faraone SV. Preliminary examination of the reliability and concurrent validity of the attention-deficit/hyperactivity disorder self-report scale v1.1 symptom checklist to rate symptoms of attention-deficit/hyperactivity disorder in adolescents. J Child Adolesc Psychopharmacol. 2012 Jun;22(3):238-44. doi: 10.1089/cap.2011.0062. Epub 2012 Apr 26. PubMed 22537184 ↗
  • Cervin M, Veas A, Piqueras JA, Martinez-Gonzalez AE. A multi-group confirmatory factor analysis of the revised children's anxiety and depression scale (RCADS) in Spain, Chile and Sweden. J Affect Disord. 2022 Aug 1;310:228-234. doi: 10.1016/j.jad.2022.05.031. Epub 2022 May 10. PubMed 35561880 ↗
  • Carlberg Rindestig F, Wiberg M, Chaplin JE, Henje E, Dennhag I. Psychometrics of three Swedish physical pediatric item banks from the Patient-Reported Outcomes Measurement Information System (PROMIS)(R): pain interference, fatigue, and physical activity. J Patient Rep Outcomes. 2021 Oct 12;5(1):105. doi: 10.1186/s41687-021-00382-2. PubMed 34637029 ↗
  • Sommer A, Grothus S, Grochowska K, Claus BB, Stahlschmidt L, Wager J. Assessing fatigue in children and adolescents: Psychometric validation of the German version of the PROMIS(R) Pediatric Short Form v2.0 - Fatigue 10a in school children and pediatric chronic pain patients. Qual Life Res. 2022 Apr;31(4):1257-1266. doi: 10.1007/s11136-021-03032-8. Epub 2021 Nov 13. PubMed 34773573 ↗
  • Fiani D, Kim JW, Hu M, Salas R, Heilbronner S, Powers J, Haque M, Dinh S, Huang X, Worthy D, Devaraj S, Xu J, Calarge C. Iron Deficiency Without Anemia and Reduced Basal Ganglia Iron Content in Youths. JAMA Netw Open. 2025 Jun 2;8(6):e2516687. doi: 10.1001/jamanetworkopen.2025.16687. PubMed 40540272 ↗
  • Truong J, Naveed K, Beriault D, Lightfoot D, Fralick M, Sholzberg M. The origin of ferritin reference intervals: a systematic review. Lancet Haematol. 2024 Jul;11(7):e530-e539. doi: 10.1016/S2352-3026(24)00103-0. PubMed 38937026 ↗
  • Revel-Vilk S, Ben-Ami T, Constantini N. Is it time to offer routine screening for iron deficiency in healthy adolescent females? Br J Haematol. 2025 Oct;207(4):1242-1247. doi: 10.1111/bjh.20243. Epub 2025 Jul 2. PubMed 40605410 ↗
  • Fiani D, Chahine S, Zaboube M, Solmi M, Powers JM, Calarge C. Psychiatric and cognitive outcomes of iron supplementation in non-anemic children, adolescents, and menstruating adults: A meta-analysis and systematic review. Neurosci Biobehav Rev. 2025 Nov;178:106372. doi: 10.1016/j.neubiorev.2025.106372. Epub 2025 Sep 11. PubMed 40945632 ↗
  • Barks A, Hall AM, Tran PV, Georgieff MK. Iron as a model nutrient for understanding the nutritional origins of neuropsychiatric disease. Pediatr Res. 2019 Jan;85(2):176-182. doi: 10.1038/s41390-018-0204-8. Epub 2018 Oct 16. PubMed 30341413 ↗
  • Soderman L, Stubbendorff A, Ladfors LV, Bolmsjo BB, Nymberg P, Wolff M. Exploring the effect of menstrual loss and dietary habits on iron deficiency in teenagers: A cross-sectional study. PLoS One. 2025 Dec 3;20(12):e0336688. doi: 10.1371/journal.pone.0336688. eCollection 2025. PubMed 41335582 ↗
  • Hallstrom E, Lofvenborg JE, Moreaus L, Sjoberg A, Winkvist A, Lindroos AK. Iron intake and iron status of Swedish adolescents with diets of varying climate impact. Eur J Nutr. 2025 Feb 15;64(2):93. doi: 10.1007/s00394-024-03572-y. PubMed 39954132 ↗
  • Auerbach M, DeLoughery TG, Tirnauer JS. Iron Deficiency in Adults: A Review. JAMA. 2025 May 27;333(20):1813-1823. doi: 10.1001/jama.2025.0452. PubMed 40159291 ↗

Individual participant data

Plan to share: No — Data will not be made public in line with the ethical approval. However, researchers will, upon reasonable request, get access to the pseudonymized data file.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2028, 14 months later.

Of 668 non-industry interventional studies with no phase under Mental Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 14 months is below that.

Counting every sponsor, half of 682 studies reached it within 29 months; a quarter within 13 and three quarters within 45.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Feb 28, 2028
CompletionEst.
Feb 28, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948876
Lead sponsor
Lund University Hospital
Collaborators
Region Halland
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Feb 28, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Hakan Jarbin, MD, PhD
Contact
hakan.jarbin@regionhalland.se
+46706778006
Rebecca Mortazavi, MD, PhD
Contact
rebecca.mortazavi@regionhalland.se
+46738011091
Matti Cervin
study chair · Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Sweden.
Hakan Jarbin, MD, PhD
principal investigator · Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Sweden; Child and Adolescent Psychiatric Clinic, Region Halland, Sweden
Sara Marie Larsson, Clinical biochemist, PhD
study chair · Department of Clinical Chemistry, Region Halland, Varberg/Halmstad Sweden; Department of Clinical Sciences, Pediatrics, Lund University, Lund, Sweden
Ingrid Larsson, RN, PhD
study chair · School of Health and Welfare, Department of Health and Nursing, Halmstad University, Halmstad, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of clinical sciences, Section of Rheumatology, Lund University, Lund, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion